Why the study?
Does losartan prevent obesity-induced glomerulopathy and upregulation of inflammatory mediators in obese Zucker rats?
Population
Seven-week-old male obese Zucker rats (a model of obesity, insulin resistance, and renal injury)
Comparison
Losartan (100 mg/L in drinking water) for 4 months vs Untreated obese Zucker rats and lean Zucker rats…
Design
Preclinical, randomized
Follow-up
4 months
Authors
Loading...
Extends AT1R blockade to obese Zucker rat glomerulopathy; leaves open translation to human obesity-related kidney disease.
Does losartan prevent obesity-induced glomerulopathy and upregulation of inflammatory mediators in obese Zucker rats?
Blockade of the angiotensin II type 1 receptor with losartan prevents obesity-induced glomerulopathy and associated inflammatory mediator upregulation in a rat model.
Xu et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: